The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 7
  • 1
    Smirnyagina, Ekaterina, Dr
    Senior Partner Life Sciences born in August 1966
    Individual (3 offsprings)
    Officer
    2021-10-08 ~ now
    OF - Director → CIF 0
  • 2
    Leuchtenberger, Mark
    Chief Executive Officer born in June 1956
    Individual (2 offsprings)
    Officer
    2022-06-06 ~ now
    OF - Director → CIF 0
  • 3
    Gray, Edward James
    Director born in April 1959
    Individual (2 offsprings)
    Officer
    2023-02-02 ~ now
    OF - Director → CIF 0
  • 4
    Menichella, Daniel
    Senior Executive In The Biotech Industry born in September 1959
    Individual (1 offspring)
    Officer
    2021-02-25 ~ now
    OF - Director → CIF 0
  • 5
    Biswas, Sumi
    Associate Professor born in July 1983
    Individual (1 offspring)
    Officer
    2017-03-10 ~ now
    OF - Director → CIF 0
  • 6
    Crawford-brunt, Andre
    Director born in March 1971
    Individual (10 offsprings)
    Officer
    2021-02-05 ~ now
    OF - Director → CIF 0
  • 7
    OXFORD SCIENCES INNOVATION PLC - 2021-09-30
    OXFORD SCIENCES PLC - 2015-03-17
    King Charles House, Park End Street, Oxford, England
    Active Corporate (11 parents, 66 offsprings)
    Person with significant control
    2018-03-02 ~ now
    PE - Ownership of shares – More than 25% but not more than 50%CIF 0
    PE - Ownership of voting rights - More than 25% but not more than 50%CIF 0
Ceased 5
  • 1
    Porter, Carolyn Breege, Dr
    Chief Business Officer born in July 1970
    Individual
    Officer
    2018-02-15 ~ 2021-02-05
    OF - Director → CIF 0
  • 2
    Wong, James Ching Tung
    Investment Principal born in June 1984
    Individual (1 offspring)
    Officer
    2020-11-13 ~ 2021-10-08
    OF - Director → CIF 0
  • 3
    Mackinnon, Lachlan Tom
    Director born in April 1993
    Individual (2 offsprings)
    Officer
    2017-03-02 ~ 2020-10-16
    OF - Director → CIF 0
  • 4
    Giebel, Lutz
    Senior Executive (Biotech) born in November 1959
    Individual
    Officer
    2021-02-05 ~ 2022-10-06
    OF - Director → CIF 0
  • 5
    University Offices, Wellington Square, Oxford, United Kingdom
    Corporate (3 offsprings)
    Person with significant control
    2017-03-02 ~ 2018-03-02
    PE - Ownership of shares – More than 25% but not more than 50%CIF 0
    PE - Ownership of voting rights - More than 25% but not more than 50%CIF 0
parent relation
Company in focus

SPYBIOTECH LIMITED

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
162023-01-01 ~ 2023-12-31
142022-04-01 ~ 2022-12-31
Intangible Assets
282,016 GBP2023-12-31
328,429 GBP2022-12-31
Property, Plant & Equipment
116,841 GBP2023-12-31
123,753 GBP2022-12-31
Fixed Assets - Investments
1 GBP2023-12-31
1 GBP2022-12-31
Fixed Assets
398,858 GBP2023-12-31
452,183 GBP2022-12-31
Debtors
Current
2,343,751 GBP2023-12-31
2,181,252 GBP2022-12-31
Cash at bank and in hand
12,084,817 GBP2023-12-31
16,367,262 GBP2022-12-31
Current Assets
14,428,568 GBP2023-12-31
18,548,514 GBP2022-12-31
Creditors
Current, Amounts falling due within one year
-3,485,566 GBP2023-12-31
-2,377,635 GBP2022-12-31
Net Current Assets/Liabilities
10,943,002 GBP2023-12-31
16,170,879 GBP2022-12-31
Total Assets Less Current Liabilities
11,341,860 GBP2023-12-31
16,623,062 GBP2022-12-31
Net Assets/Liabilities
11,267,516 GBP2023-12-31
16,552,258 GBP2022-12-31
Equity
Called up share capital
6,413 GBP2023-12-31
6,408 GBP2022-12-31
6,312 GBP2022-04-01
Share premium
28,762,998 GBP2023-12-31
28,762,853 GBP2022-12-31
28,698,889 GBP2022-04-01
Other miscellaneous reserve
1,128,274 GBP2023-12-31
542,548 GBP2022-12-31
365,657 GBP2022-04-01
Retained earnings (accumulated losses)
-18,630,169 GBP2023-12-31
-12,759,551 GBP2022-12-31
-9,696,339 GBP2022-04-01
Equity
11,267,516 GBP2023-12-31
16,552,258 GBP2022-12-31
19,374,519 GBP2022-04-01
Profit/Loss
Retained earnings (accumulated losses)
-5,870,618 GBP2023-01-01 ~ 2023-12-31
-3,100,841 GBP2022-04-01 ~ 2022-12-31
Comprehensive Income/Expense
Retained earnings (accumulated losses)
-5,870,618 GBP2023-01-01 ~ 2023-12-31
-3,100,841 GBP2022-04-01 ~ 2022-12-31
Comprehensive Income/Expense
-5,870,618 GBP2023-01-01 ~ 2023-12-31
-3,100,841 GBP2022-04-01 ~ 2022-12-31
Issue of Equity Instruments
Called up share capital
5 GBP2023-01-01 ~ 2023-12-31
96 GBP2022-04-01 ~ 2022-12-31
Issue of Equity Instruments
150 GBP2023-01-01 ~ 2023-12-31
64,060 GBP2022-04-01 ~ 2022-12-31
Equity - Income/Expense Recognised Directly
Called up share capital
5 GBP2023-01-01 ~ 2023-12-31
96 GBP2022-04-01 ~ 2022-12-31
Retained earnings (accumulated losses)
37,629 GBP2022-04-01 ~ 2022-12-31
Equity - Income/Expense Recognised Directly
585,876 GBP2023-01-01 ~ 2023-12-31
278,580 GBP2022-04-01 ~ 2022-12-31
Amounts Owed by Group Undertakings
Current
461,772 GBP2023-12-31
485,173 GBP2022-12-31
Other Debtors
Current
309,429 GBP2023-12-31
1,552,809 GBP2022-12-31
Prepayments/Accrued Income
Current
221,238 GBP2023-12-31
143,270 GBP2022-12-31
Amount of corporation tax that is recoverable
Current
1,351,312 GBP2023-12-31
Cash and Cash Equivalents
12,084,817 GBP2023-12-31
16,367,262 GBP2022-12-31
Other Remaining Borrowings
Current
3,157 GBP2023-12-31
1,434 GBP2022-12-31
Trade Creditors/Trade Payables
Current
428,643 GBP2023-12-31
314,340 GBP2022-12-31
Taxation/Social Security Payable
Current
34,386 GBP2023-12-31
31,548 GBP2022-12-31
Other Creditors
Current
27,584 GBP2023-12-31
11,821 GBP2022-12-31
Accrued Liabilities/Deferred Income
Current
2,991,796 GBP2023-12-31
2,018,492 GBP2022-12-31
Creditors
Current
3,485,566 GBP2023-12-31
2,377,635 GBP2022-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
4,000,000 shares2023-12-31
4,000,000 shares2022-12-31
Class 2 ordinary share
5,140,056 shares2023-12-31
5,135,056 shares2022-12-31
Class 3 ordinary share
7,900,387 shares2023-12-31
7,900,387 shares2022-12-31
Class 4 ordinary share
833,333 shares2023-12-31
833,333 shares2022-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
Amounts falling due within one year
93,067 GBP2023-12-31
121,973 GBP2022-12-31
Between one and five year
277,446 GBP2023-12-31
91,480 GBP2022-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
370,513 GBP2023-12-31
213,453 GBP2022-12-31

  • SPYBIOTECH LIMITED
    Info
    Registered number 10649320
    7600 The Quorum, Alec Issigonis Way, Oxford Business Park North, Oxford OX4 2JZ
    Private Limited Company incorporated on 2017-03-02 (8 years 4 months). The company status is Active.
    The last date of confirmation statement was made at 2025-03-01
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.
© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.